Is SynergyRx GLP-1 Legitimate? Platform Lists Compounded Semaglutide at $200 With Oral Tablet Options
Direct Meds GLP-1 Medications Platform Maintains LegitScript Certification as New Year Weight Loss Interest Peaks Amid Compounding Regulatory Shifts
Best Peptides for Boosting Growth Hormone: ReadyRx Lists Prescription Sermorelin in Injectable and Needle-Free Formats for 2026
Best Fat Burner For Men 2026: Effective Fat Burning Supplements For Men’s Belly Fat Launched By Wolfson Brands Ltd
Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways
No safety concerns or dose limiting toxicities observed SCY-247 was able to achieve target exposures at doses lower than our...
~ Topline results from the EXPLORE-OSA trial are anticipated in 1Q 2026 ~ RADNOR, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE)...
GARDNER, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and...
Spring® Scope delivers the largest working channel of any flexible single-use cystoscope, enhancing visualization and patient comfortSOUTH SAN FRANCISCO, Calif.,...
DES MOINES, Iowa, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Stride Autism Centers, a leading provider of center-based early intervention ABA...
The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being...
SEATTLE, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to...
-- AjD Represents an Area of Significant Unmet Need; No U.S. Food and Drug Administration (FDA)-Approved Therapies Available -- --...
BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company...
Carlsbad, CA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or “the Company”) today announced the...
Based on previously reported positive Phase 1 results, Kynexis is advancing KYN-5356, a first-in-class KAT-II inhibitor, into a Phase 2...
Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting...
NEUMÜNSTER, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tilray Medical a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX:...
Additional time enables LAVA Therapeutics to address potential liabilities and confirm net cash to be delivered to Shareholders. LAVA Therapeutics...
WAYNE, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...
Focal One® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment Option Focal One Robotic HIFU Patient Story...
Canada’s Largest Charity Dedicated to Lung Health Responds to the Launch of a Canada Post StrikeTORONTO, Sept. 30, 2025 (GLOBE...
RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics, a regenerative medicine company developing biologic drug therapies...
BOSTON, Sept. 30, 2025 /PRNewswire/ -- BrainCo holds that the true value of technology lies in expanding the boundaries of...
Data2Evidence meets FeederNet: Joining forces for scalable, standardized, and responsible health research infrastructure SEOUL, South Korea and POTSDAM, Germany, Sept....
